Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio (CABA)
NASDAQ:CABA
Holding CABA?
Track your performance easily
CABA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.76 - $26.35
Previous Close$2.29
Volume697.46K
Average Volume (3M)2.37M
Market Cap
$112.42M
Enterprise Value-$55.86M
Total Cash (Recent Filing)$183.01M
Total Debt (Recent Filing)$15.22M
Price to Earnings (P/E)―
Beta3.50
Next Earnings
Mar 13, 2025EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding48,877,164
10 Day Avg. Volume1,453,033
30 Day Avg. Volume2,366,175
Standard Deviation0.39
R-Squared0.10
Alpha0.00536
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.52
Forecast
1Y Price Target
$17.88Price Target Upside677.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Cabaletta Bio News
PremiumCompany Announcements
Cabaletta Bio Reports Q3 2024 Financial Results
PremiumCompany Announcements
Cabaletta Bio’s Promising Clinical Data on CABA-201Bulls Say, Bears Say
Bulls Say
Clinical TrialsCABA-201 demonstrates promising activity across multiple autoimmune diseases, with the potential for drug-free clinical responses.
Market PotentialThe potential for CABA-201 to capture more market share, particularly in women of childbearing age, could provide opportunity for growth.
Patient EnrollmentThe company now has 40 active clinical trial sites, an increase from the 22 reported during its second-quarter earnings, and is continuing to initiate and onboard new clinical sites.
Bears Say
Competitive PressureShares are down -88% YTD as worry over CABA-201's safety profile, competition from BiSpecs & allogeneic CAR T programs in I&I, and its cash overhang have negatively impacted shares and sentiment.
Financial PerformanceThe company only has cash into 1H26, which will weigh on shares and cap upside for the stock.
Safety ConcernsShares are down largely due to limited data updates from CABA-201, the reported Grade 4 ICANS case, and the company's capital overhang.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $1.76 and its highest was $26.35 in the past 12 months.
What is Cabaletta Bio’s market cap?
Currently, no data Available
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is Mar 13, 2025 which is in 73 days.
How were Cabaletta Bio’s earnings last quarter?
Cabaletta Bio released its earnings results on Nov 14, 2024. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.596 by -$0.024.
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -$0.64.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 48,877,163 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Cabaletta Bio reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.596. Following the earnings report the stock price went down -5.736%.
Which hedge fund is a major shareholder of Cabaletta Bio?
Among the largest hedge funds holding Cabaletta Bio’s share is Graham Capital Management, L.P.. It holds Cabaletta Bio’s shares valued at 111K.
---
Cabaletta Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.88 (677.39% Upside)
$17.88 (677.39% Upside)
Blogger Sentiment
Bullish
CABA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.19%
12-Months-Change
Fundamentals
Return on Equity
-62.16%
Trailing 12-Months
Asset Growth
17.96%
Trailing 12-Months
Company Description
Cabaletta Bio
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
---
CABA Stock 12 Month Forecast
Average Price Target
$17.88
▲(677.39% Upside)
Technical Analysis
Best Analysts Covering CABA
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+184.22%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +184.22% per trade.
---